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Abstract
Background: Tubal ectopic pregnancy (tEP) is the most common life-threatening condition in gynaecology. Treatment
options include surgery and medical management. Stable women with tEPs with pre-treatment serum human chorionic
gonadotrophin (hCG) levels < 1000 IU/L respond well to outpatient medical treatment with intramuscular methotrexate.
However, tEPs with hCG > 1000 IU/L can take significant time to resolve with methotrexate and require multiple outpatient
monitoring visits. In pre-clinical studies, we found that tEP implantation sites express high levels of epidermal growth factor
receptor. In early-phase trials, we found that combination therapy with gefitinib, an orally active epidermal growth factor
receptor antagonist, and methotrexate resolved tEPs without the need for surgery in over 70% of cases, did not cause
significant toxicities, and was well tolerated. We describe the protocol of a randomised trial to assess the efficacy of
combination gefitinib and methotrexate, versus methotrexate alone, in reducing the need for surgical intervention for tEPs.
Methods and analysis:We propose to undertake a multi-centre, double-blind, placebo-controlled, randomised trial (around
70 sites across the UK) and recruit 328 women with tEPs (with pre-treatment serum hCG of 1000–5000 IU/L). Women will be
randomised in a 1:1 ratio by a secure online system to receive a single dose of intramuscular methotrexate (50 mg/m2) and
either oral gefitinib or matched placebo (250 mg) daily for 7 days. Participants and healthcare providers will remain blinded
to treatment allocation throughout the trial. The primary outcome is the need for surgical intervention for tEP. Secondary
outcomes are the need for further methotrexate treatment, time to resolution of the tEP (serum hCG ≤ 15 IU/L), number of
hospital visits associated with treatment (until resolution or scheduled/emergency surgery), and the return of menses by 3
months after resolution. We will also assess adverse events and reactions until day of resolution or surgery, and participant-
reported acceptability at 3 months.
Discussion: A medical intervention that reduces the need for surgery and resolves tEP faster would be a favourable
treatment alternative. If effective, we believe that gefitinib and methotrexate could become standard care for stable tEPs.
Trial registration: ISRCTN Registry ISRCTN67795930. Registered 15 September 2016.
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Background
Tubal ectopic pregnancy (tEP) is a significant contributor
to maternal morbidity and mortality in both the developed
and developing world [1, 2]. Health economic models sug-
gest that medical management with a single intramuscular
injection of methotrexate (MTX) is a cost-effective treat-
ment for haemodynamically stable women with tEP, but
there is a significant risk of treatment failure if the
pre-treatment human chorionic gonadotrophin (hCG)
levels are > 1500 IU/L. Treatment failure carries a subse-
quent risk of emergency laparoscopic surgical excision
(with its inherent risks of damage to visceral organs and
impact on subsequent fertility) [3]. In addition, women
with higher hCG levels take a significant time to resolve
with MTX and require multiple outpatient monitoring
visits. Women with lower pre-treatment serum hCG levels
(< 1000 IU/L) can be managed with MTX, or by expectant
management without medical intervention [4, 5]. There
exists a need for more effective medical treatments for
tEP with higher hCG levels to reduce the need for
emergency surgery and to reduce the time to resolution
associated with MTX management.
Gefitinib is an orally active epidermal growth factor re-
ceptor (EGFR) antagonist licensed to treat non-small cell
lung cancer [6]. In pre-clinical studies, we found that
tEP implantation sites express high levels of EGFR and
that gefitinib augments MTX-induced regression of
pregnancy-like tissue [7]. To translate this into clinical
care, we performed a phase I, single-arm, open-label,
dose-escalation trial (GEM1) administering a combination
of 250 mg oral gefitinib (one dose (n = 3), three daily doses
(n = 3), and seven daily doses (n = 6)) and intramuscular
MTX (50 mg/m2) to 12 women with tEP [8]. Resolution
(fall in serum hCG to ≤ 15 IU/l) with combination therapy
(up to seven doses of oral gefitinib with the MTX) was
faster than the median time for tEPs to resolve with MTX
alone when compared with historic controls (21 vs
32 days). We then carried out a phase II, single-arm,
open-label trial (GEM2) administering a combination of 7
days of 250 mg oral gefitinib and intramuscular MTX
(50 mg/m2) to 28 women with tEP [9]. The trial has been
successfully completed [10].
MTX is an established standard in the treatment of tEP,
and adverse reactions such as stomatitis and nausea are
usually mild and self-limiting. More severe adverse reac-
tions are rare but include hepatotoxicity, myelosuppres-
sion, and nephrotoxicity. Regarding the safety of gefitinib,
data from post-marketing surveillance representing over
92,000 patients suggest that EGFR inhibitors are largely
free of serious side effects (Food and Drug Administration
(FDA) report) [11]. Of note, the data on tolerability are
based on patients taking gefitinib daily on an ongoing, in-
definite basis, after primary treatment of lung cancer.
Diarrhoea and skin rash are the most common side effects
(20–30%). The skin rash, described as acneiform, can be
severe, but is generally self-limited. These side effects are
quite common; in GEM1 we noted that 67% of women
developed a transient acneiform rash and 42% had
diarrhoea [8].
Objectives
The primary objective of this trial is to compare the effi-
cacy of a combination of gefitinib and MTX to treat tEP
(hCG ≥ 1000 IU/L and ≤ 5000 IU/L) with MTX alone in
terms of the need for emergency (rescue) surgery. In our
secondary objectives, we will evaluate the need for a
second dose of MTX, time to resolution of pregnancy
(serum hCG ≤ 15 IU/L), number of associated hospital
visits, time of return to menses, and the safety, tolerabi-
lity, and acceptability of the combination treatment.
Methods
Study design
This will be a phase III, multi-centre, double-blind,
placebo-controlled, randomised trial in around 70 UK
early pregnancy units. At the time of writing (19 May
2018), GEM3 is recruiting from 54 sites but expansion
to 70 sites is in progress. The protocol described in the
manuscript is an abbreviated version. The full protocol
used by investigators can be found at https://www.bir-
mingham.ac.uk/research/activity/mds/trials/bctu/trials/
womens/gem3/index.aspx. This protocol has been pre-
pared in accordance with Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT),
and a checklist is provided as Additional file 1.
Inclusion and exclusion criteria
Women diagnosed with a haemodynamically stable tEP
diagnosed on ultrasound with serum hCG concentra-
tions ≥ 1000 IU/L and ≤ 5000 IU/L and deemed suitable
for MTX treatment by their attending clinical team as
per local protocols will be screened for eligibility for the
GEM3 trial against the criteria listed in Table 1.
Participant enrolment
Potential participants will be identified by a member of
their clinical care team and provided with a patient in-
formation sheet. All eligible women will have the oppor-
tunity to discuss the trial with a member of the clinical
research team. Consent will be taken once the patient
has had ample time to read the patient information
sheet and had her questions answered. Consent will be
obtained by a member of staff who has had specific trial
training and Good Clinical Practice (GCP) training, or
targeted trial-specific GCP training.
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Participant log
The clinical research team will keep an electronic log of
women who fulfil the eligibility criteria including those
who are invited to participate in the study, women
recruited, and those who leave the trial early. Reasons
for non-recruitment (e.g. non-eligibility, refusal to par-
ticipate) will be recorded. We will attempt to collect
reasons for non-participation from women who decline
to take part. No further information will be collected on
ineligible women (Fig. 1).
Randomisation and blinding
Participants will be randomised individually into the
GEM3 trial in an equal ratio of MTX/gefitinib or MTX/
placebo. Randomisation will be performed via a secure
web-based service provided by the Birmingham Clinical
Trials Unit (BCTU). A minimisation procedure using a
computer-based algorithm will be used to avoid
chance imbalances in baseline serum hCG concentra-
tions (< 1500 IU/L, ≥ 1500 to < 2500 IU/L, ≥ 2500 IU/L),
body mass index (BMI; < 25, ≥ 25), tEP size (< 2 cm, ≥
2 cm), and recruiting centre. To avoid any possibility of
the treatment allocation becoming too predictable, a ran-
dom factor will be included within the algorithm whereby
allocation to the minimised treatment group will occur
with a probability of < 1. The BCTU will electronically
manage the drug supply via a bespoke database. Following
randomisation and allocation, the relevant staff will be
emailed with the trial identifier, the date of treatment, and
the treatment bottle allocation.
Intervention
Randomised women will be given a single-dose injection
of intramuscular MTX (50 mg/m2) with seven daily oral
doses of gefitinib or matched placebo (250 mg). No
changes in dose will be permitted. The study treatment
will be started on the same day as the MTX is adminis-
tered with the remaining treatment being taken in the
participant’s home. Participants will be asked to take the
study drug at approximately the same time each day.
The placebo and active drug will appear identical, thus
blinding trial participants, care providers, and outcome
assessors.
Outcomes and assessments
A summary of study assessments and time points is
given in Fig. 2. Our primary outcome is surgical inter-
vention for treatment of the index EP (salpingectomy/
salpingostomy by laparoscopy/laparotomy).
The secondary outcomes are:
1. The need for a second dose of MTX.
2. Number of days to resolution of tEP. Resolution is
defined by serum hCG levels falling to non-
pregnancy levels (hCG ≤ 15 IU/L), which corre-
sponds to a negative urinary pregnancy test using
the most sensitive assays.
3. Number of treatment-associated hospital visits until
resolution or emergency ‘rescue’ surgery
4. Return to menses, assessed 3 months post-
resolution by telephone interview.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Diagnosis of either;
1. Definite tubal ectopic pregnancy (EP) (extra-uterine
gestational sac with yolk sac and/or embryo, without cardiac
activity on ultrasound scan (USS));
or
2. Clinical decision of probable tubal EP (extrauterine
sac-like structure or inhomogeneous adnexal mass on USS
with a background of sub-optimal serum human chorionic
gonadotrophin (hCG) concentrations
(on at least 2 different days)
Clinical decision made for treatment of tubal EP with methotrexate
(MTX)
Able to understand all information (written and oral) presented
(using an interpreter if necessary) and provide signed consent
18–50 years of age at time of randomisation
Pre-treatment serum hCG level of 1000–5000 IU/L (within
1 calendar day of randomisation)
Clinically stable
Haemoglobin between 100 and 165 g/L no more than
3 calendar days before randomisation
Able to comply with treatment and willing to participate
in follow-up
Exclusion criteria
Pregnancy of unknown location (PUL)
Evidence of intra-uterine pregnancy
Breastfeeding
Hypersensitivity to gefitinib
EP mass on ultrasound greater than 3.5 cm (mean dimensions)
Evidence of significant intra-abdominal bleed on USS defined
by echogenic free fluid above the uterine fundus or surrounding
ovary within 1 calendar day of treatment
Significant abdominal pain, guarding/rigidity
Clinically significant abnormal liver/renal/haematological
indices noted no more than 3 calendar days before
randomisation
Galactose intolerance
Significant dermatological disease, e.g. severe psoriasis/eczema
Significant pulmonary disease, e.g. severe/uncontrolled asthma
Significant gastrointestinal illness, e.g. Crohn’s disease/ulcerative
colitis
Participating in any other clinical trial of an investigational
medicinal product
Previous participation in GEM3
Japanese ethnicity
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Fig. 1 CONSORT flow diagram. MTX methotrexate
Fig. 2 Schedule of enrolment, interventions, and assessments. hCG human chorionic gonadotrophin
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5. Safety and tolerability: women will be assessed
clinically (at each contact as per local policies) and
biochemically (haematological, renal, and liver
function tests between days 14–21 post-treatment)
and these will be repeated if deemed clinically
significant.
6. Acceptability of treatment: assessed 3 months post-
resolution by participant-reported Likert scores via
a telephone interview.
Participants will be asked at each visit if they have
taken the drug so that the researcher can record how
much study drug has been taken.
Sample size
We have calculated the sample size based on data taken
from our GEM2 study [12], our published cohort data
[13, 14], and an audit of Edinburgh and Imperial of
women undergoing usual care (unpublished data 2012;
focusing on tEP patients with serum hCG > 1000 IU/L).
The cohort and audit data suggest a 30% rate of surgical
intervention in the MTX group, with 15% expected in
the gefitinib plus MTX group (actual figure from GEM2
was 14% but this has been conservatively rounded up).
To detect this absolute difference in proportions of 15%
with 90% power and an alpha error rate of 5%, a total of
322 participants would need to be randomised (161 per
group). In our retrospective Scottish cohort of 397
women, 2 were lost to follow-up (0.5%) [14]. In a na-
tional audit of 222 Scottish women, no women were lost
to follow-up (unpublished data 2007; Ectopic Pregnancy:
Scottish Outcomes with Methotrexate; Scottish Programme
for Clinical Effectiveness in Reproductive Health). Assu-
ming and adjusting for a 2% loss to follow-up rate, 328
participants need to be recruited.
Statistical analysis
A separate statistical analysis plan, providing a detailed
description of the planned analysis, has been prepared
and reviewed by the Data Monitoring Committee
(DMC), and a brief outline is described here. Analysis
will be by intention to treat. Every attempt will be made
to gather data on all women randomised, irrespective of
compliance with the treatment protocol. Point estimates,
95% confidence intervals and p values from two-sided
tests will be calculated for all main outcome measures.
We will use a mixed effects log-binomial regression
model adjusting for the minimisation variables (all fixed
effects apart from centre which will be a random effect)
to calculate the relative risk and 95% confidence for the
primary outcome; a chi-squared test will be used to de-
termine statistical significance of the group parameter in
the model. In the situation where we have convergence
issues with the log binomial we will revert to a Poisson
regression model incorporating robust standard errors.
Other dichotomous secondary outcomes (e.g. need for
additional treatment) will be analysed in the same fash-
ion as the primary outcome. Time from randomisation
to successful resolution will be analysed using a Cox
proportional hazards model. Standard methods will be
used to analyse other outcomes. Tests for statistical het-
erogeneity will be performed prior to any examination of
effect estimate within subgroups. Sensitivity analyses will
be performed on the primary outcome to investigate the
impact of missing data.
Data management and monitoring
Information will be extracted from the clinical record into
the case report form (CRF). Data will be collected as it be-
comes available, i.e. at or shortly after each patient visit by
members of the clinical team supported by research staff.
We will collect reasons for missing data. All data generated
from the study will be stored anonymously in a bespoke
database created by the BCTU. Participants will be allo-
cated a unique number. All data will be stored on a Bir-
mingham University server with limited access in
accordance with the Data Protection Act (UK). During the
period of recruitment to the study, interim analyses of
major endpoints will be supplied, in strict confidence, to an
independent DMC along with updates on results of other
related studies, and any other analyses that the DMC may
request. The DMC will advise the chair of the Trial Steering
Committee (TSC) if, in their view, any of the randomised
comparisons in the trial have provided both (a) “proof
beyond reasonable doubt” that for all, or for some, types of
patient one particular treatment is definitely indicated or
definitely contraindicated in terms of a net difference in the
major endpoints, and (b) evidence that might reasonably be
expected to influence the patient management of many
clinicians who are already aware of the other main trial
results. Appropriate criteria of proof beyond reasonable
doubt cannot be specified precisely, but a difference of at
least p < 0.001 (similar to Haybittle-Peto stopping boun-
dary) in an interim analysis of a major endpoint may be
needed to justify halting, or modifying, the study prema-
turely. If this criterion were to be adopted, it would have
the practical advantage that the exact number of interim
analyses would be of little importance, so no fixed schedule
is proposed. The TSC can then decide whether to close or
modify any part of the trial. Unless this happens, however,
the central trial management group, the TSC, the investiga-
tors, and all of the central administrative staff (except the
statisticians who supply the confidential analyses) will
remain unaware of the interim results.
Safety assessment
Information on adverse events will be collected at each
contact with the participants during routine clinical
May et al. Trials          (2018) 19:643 Page 5 of 8
appointments. Any serious adverse events (SAEs) that
occur will be reported to the trial sponsor (University of
Edinburgh and NHS Lothian) and Astra Zeneca accor-
ding to their respective timelines and followed up until
resolution of the event. In-patient observation and surgi-
cal treatment for EP will not be considered a SAE, nor
will any planned hospitalisation or hospitalisation for
pre-existing conditions. These will be recorded as
adverse events (AEs) but will not be reported as SAEs.
All AEs and SAEs will be recorded from the time a par-
ticipant signs the consent form to take part in the study
until resolution. Participants will be asked to return any
unused drug to the research team for safe disposal in the
pharmacy. All participants will be given an emergency
card to carry while participating in the study. The mech-
anism for code breaking will include an online code
break facility which will be part of the BCTU randomisa-
tion database with restricted access as to who can break
the blind. The sponsor will have access to the random-
isation database in case of potential serious unexpected
serious adverse reactions (SUSARs).
Ethics and dissemination
This trial was externally peer reviewed by the UK
National Institute for Health Research (NIHR) as part of
the process of obtaining funding from the Efficacy and
Mechanistic Evaluation (EME) programme. Ethical
approval was obtained from the Scotland A Research
Ethics Committee (16/SS/0014) on 29 February 2016.
Data will be presented at international conferences and
published in peer-reviewed journals. We will make the
information available to the public through national
bodies and charities, e.g. the Ectopic Pregnancy Trust.
Discussion
If effective, we believe that this combination gefitinib
and MTX could become the standard of care for stable
tEPs. We believe that many clinicians would agree that
an intervention that is shown to be significantly better
than MTX in reducing the risk of surgery (our primary
outcome) and resolves tEPs faster would be a better
treatment alternative. The avoidance of surgery in the
management of tEPs avoids surgical and anaesthetic risk
for the patient, and is likely to result in cost saving for
healthcare services. There is limited evidence regarding
the impact on fertility of treatment options for tEPs;
however, previous randomised controlled trials have not
identified significant differences in fertility rates follow-
ing medical or surgical treatment [15, 16].
In this randomised trial, we have chosen endpoints
that are highly clinically relevant and eligibility criteria
that reflect clinical practice in patients undergoing
medical treatment of tEP and, as such, we believe that
the results will be generalisable. Allocation will be
strictly random and trial participants, care providers,
and outcome assessors will be blinded to the interven-
tion. We anticipate high ascertainment in terms of the
primary outcome. We acknowledge the trial’s limitations,
including the potential for unblinding that may happen
if participants experience side effects associated with
gefitinib, notably the skin rash. The decision for interven-
tion will be made by individual sites and there may exist
variation in the propensity to intervene between sites.
The post-marketing surveillance data regarding gefitinib
supports its safety in terms of a side-effect profile as well as
tolerability. Of particular note, interstitial lung disease
(ILD) is a very rare but a serious side effect of gefitinib. It is
a thickening of the lung parenchyma that can be fatal in a
third of cases. Of the 31,045 patients in the USA who took
gefitinib (reported to the FDA), 84 developed ILD (0.3%).
However, the median length of time that gefitinib was taken
for those who developed ILD was 42 days. In contrast, we
plan to administer 250 mg gefitinib tablets orally, one daily
for only 7 days, in addition to MTX. This is an extremely
short duration of treatment compared with gefitinib’s
current marketing indications and existing data usage. Fur-
thermore, it is unclear whether ILD also occurred in these
patients taking gefitinib indefinitely because of the presence
of concurrent lung cancer. There have been almost no re-
ports of ILD occurring among patients taking Cetuximab (a
neutralising monoclonal epidermal growth factor antibody)
to treat colon cancer. Thus, we believe the probability of
our cohort developing this condition is negligible.
In our first trial (GEM1), we presented encouraging data to
suggest this treatment option held promise. We compared six
participants with a pre-treated serum hCG 1000–3000 IU/L
and treated with gefitinib and MTX with 71 historical con-
trols who presented to our clinical service (with the same
serum hCG range) and were treated with MTX alone [8].
The serum hCG levels among those treated with the combin-
ation fell considerably more precipitously than those treated
with MTX alone and the tEPs resolved 34% faster. We also
successfully treated eight participants with extra-tubal EPs
with combination gefitinib and MTX. Finally, we have com-
pleted a single arm trial of 28 women with tEPs who had a
pre-treatment serum hCG between 1000 and 10,000 IU/L
[10]. However, all these were single-arm, open-label trials. As
such, we have embarked on this large randomised trial to
demonstrate that adding gefitinib to MTX is significantly
more effective than MTX alone. It has been designed with a
primary outcome that is highly clinically relevant.
Trial status
Currently recruiting. Trial start date 2 November 2016.
Anticipated recruitment end date is December 2019.
Protocol version 6, 12 April 2017.
See https://www.birmingham.ac.uk/research/activity/
mds/trials/bctu/trials/womens/gem3/index.asp.
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Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 125 kb)
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